PET Criteria by Cancer Type from Imaging Interpretation to Treatment Response Assessment: Beyond FDG PET Score.
FuMeGa
NAFCIST
NETPET
PPP
PRIMARY
PSMA-RADS
Pro-PET
RECIP 1.0
SSTR-RADS
miTNM
non-FDG PET criteria
Journal
Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444
Informations de publication
Date de publication:
22 Feb 2023
22 Feb 2023
Historique:
received:
18
01
2023
revised:
30
01
2023
accepted:
17
02
2023
medline:
30
3
2023
entrez:
29
3
2023
pubmed:
30
3
2023
Statut:
epublish
Résumé
in recent years, the role of positron emission tomography (PET) and PET/computed tomography (PET/CT) has emerged as a reliable diagnostic tool in a wide variety of pathological conditions. This review aims to collect and review PET criteria developed for interpretation and treatment response assessment in cases of non-[ A wide literature search of the PubMed/MEDLINE, Scopus and Google Scholar databases was made to find relevant published articles about non-[ The comprehensive computer literature search revealed 183 articles. On reviewing the titles and abstracts, 149 articles were excluded because the reported data were not within the field of interest. Finally, 34 articles were selected and retrieved in full-text versions. available criteria are a promising tool for the interpretation of non-FDG PET scans, but also to assess the response to therapy and therefore to predict the prognosis. However, oriented clinical trials are needed to clearly evaluate their impact on patient management.
Sections du résumé
BACKGROUND
BACKGROUND
in recent years, the role of positron emission tomography (PET) and PET/computed tomography (PET/CT) has emerged as a reliable diagnostic tool in a wide variety of pathological conditions. This review aims to collect and review PET criteria developed for interpretation and treatment response assessment in cases of non-[
METHODS
METHODS
A wide literature search of the PubMed/MEDLINE, Scopus and Google Scholar databases was made to find relevant published articles about non-[
RESULTS
RESULTS
The comprehensive computer literature search revealed 183 articles. On reviewing the titles and abstracts, 149 articles were excluded because the reported data were not within the field of interest. Finally, 34 articles were selected and retrieved in full-text versions.
CONCLUSIONS
CONCLUSIONS
available criteria are a promising tool for the interpretation of non-FDG PET scans, but also to assess the response to therapy and therefore to predict the prognosis. However, oriented clinical trials are needed to clearly evaluate their impact on patient management.
Identifiants
pubmed: 36983767
pii: life13030611
doi: 10.3390/life13030611
pmc: PMC10057339
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
J Nucl Med. 2021 Apr;62(4):514-520
pubmed: 32859702
J Nucl Med. 2020 Apr;61(4):533-539
pubmed: 31562226
Nucl Med Commun. 2022 Sep 1;43(9):1034-1041
pubmed: 35833288
Clin Nucl Med. 2022 Jan 1;47(1):26-35
pubmed: 34874347
J Nucl Med. 2009 Sep;50(9):1427-34
pubmed: 19690033
Theranostics. 2017 Mar 1;7(5):1149-1158
pubmed: 28435454
EJNMMI Res. 2021 Aug 21;11(1):76
pubmed: 34417907
J Nucl Med. 2019 Sep;60(9):1266-1269
pubmed: 30850506
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Clin Nucl Med. 2020 Jun;45(6):448-450
pubmed: 32349093
Ital J Gastroenterol Hepatol. 1999 Oct;31 Suppl 2:S219-23
pubmed: 10604135
Pharmaceuticals (Basel). 2022 Oct 20;15(10):
pubmed: 36297404
Pharmaceutics. 2022 Sep 22;14(10):
pubmed: 36297443
Tomography. 2022 Oct 27;8(6):2639-2647
pubmed: 36412679
J Clin Oncol. 2016 Feb 20;34(6):588-96
pubmed: 26712231
Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):84-91
pubmed: 26323576
PET Clin. 2014 Oct;9(4):355-70, v
pubmed: 26050942
Clin Nucl Med. 2020 Mar;45(3):187-194
pubmed: 31977479
Nucl Med Commun. 2020 Aug;41(8):759-767
pubmed: 32453205
J Nucl Med. 2021 Mar 31;:
pubmed: 33789932
J Clin Oncol. 2008 May 1;26(13):2124-30
pubmed: 18445841
J Nucl Med. 2010 Sep;51(9):1349-56
pubmed: 20720050
Cancers (Basel). 2022 Aug 21;14(16):
pubmed: 36011032
Front Neurol. 2021 May 20;12:671867
pubmed: 34093419
J Clin Oncol. 2016 Apr 20;34(12):1402-18
pubmed: 26903579
Oncotarget. 2020 Feb 11;11(6):589-599
pubmed: 32110279
J Nucl Med. 2019 Apr;60(4):511-516
pubmed: 30190303
Eur J Nucl Med Mol Imaging. 2018 Apr;45(4):602-612
pubmed: 29185010
J Nucl Med. 2018 Dec;59(12):1857-1864
pubmed: 30190304
Curr Probl Cancer. 2021 Oct;45(5):100797
pubmed: 34706830
Nucl Med Commun. 2020 Oct;41(10):1040-1046
pubmed: 32732596
J Urol. 2016 May;195(5):1436-1443
pubmed: 26682756
J Nucl Med. 2018 Mar;59(3):479-485
pubmed: 28887401
Diagnostics (Basel). 2021 Apr 07;11(4):
pubmed: 33917238
J Nucl Med. 2018 Mar;59(3):469-478
pubmed: 29123012
Eur J Nucl Med Mol Imaging. 2013 May;40(5):800-16
pubmed: 23389427
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881
J Nucl Med. 2020 May;61(5):678-682
pubmed: 31806774
Br J Cancer. 2023 Feb;128(4):549-555
pubmed: 36434154
J Nucl Med. 2019 May;60(5):577-584
pubmed: 30796171
Nucl Med Commun. 2020 Oct;41(10):1095-1099
pubmed: 32732598
Quant Imaging Med Surg. 2022 Apr;12(4):2427-2440
pubmed: 35371938
J Cancer Res Clin Oncol. 2022 Jun;148(6):1299-1311
pubmed: 35217902
J Nucl Med. 2021 Sep 1;62(9):1278-1284
pubmed: 33579809
ESMO Open. 2019 Feb 28;4(1):e000439
pubmed: 30962954
J Nucl Med. 2022 Nov;63(11):1651-1658
pubmed: 35422442
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):376-383
pubmed: 29124281
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1626-1638
pubmed: 33604691
J Nucl Med. 2017 Nov;58(11):1718-1726
pubmed: 28818983
Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1588-1601
pubmed: 28547177
EJNMMI Res. 2021 Jan 6;11(1):3
pubmed: 33409930
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
Cancers (Basel). 2022 Mar 31;14(7):
pubmed: 35406542
EJNMMI Res. 2021 Oct 19;11(1):109
pubmed: 34665337
Oncotarget. 2016 Sep 6;7(36):58105-58110
pubmed: 27517621
Nucl Med Commun. 2019 Dec;40(12):1250-1255
pubmed: 31584465
Pharmaceutics. 2022 Jun 16;14(6):
pubmed: 35745849
Cancers (Basel). 2022 Jan 06;14(2):
pubmed: 35053434
J Nucl Med. 2020 Dec;61(12):1779-1785
pubmed: 32303599
Int J Mol Sci. 2021 Apr 16;22(8):
pubmed: 33923839
J Nucl Med. 2015 May;56(5):668-74
pubmed: 25791990
J Nucl Med. 2017 Sep;58(9):1421-1428
pubmed: 28360208
J Nucl Med. 2007 Apr;48(4):508-18
pubmed: 17401086
J Nucl Med. 2001 Dec;42(12):1856-62
pubmed: 11752085
Cancers (Basel). 2022 May 19;14(10):
pubmed: 35626105
AJR Am J Roentgenol. 2007 Apr;188(4):1109-13
pubmed: 17377055
Clin Nucl Med. 2022 Jun 1;47(6):480-487
pubmed: 35426853
Nucl Med Commun. 2021 May 1;42(5):566-574
pubmed: 33560718
J Clin Med. 2022 Jan 26;11(3):
pubmed: 35160067
Eur J Nucl Med Mol Imaging. 2021 Feb;48(2):469-476
pubmed: 32617640
J Nucl Med. 2018 Jul;59(7):1085-1091
pubmed: 29572257
Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1622-1635
pubmed: 28536833
EJNMMI Res. 2022 Oct 9;12(1):66
pubmed: 36210356
Mol Imaging Biol. 2016 Jun;18(3):411-9
pubmed: 27080322
Clin Transl Imaging. 2022;10(6):687-695
pubmed: 35919380
Clin Nucl Med. 2022 Aug 1;47(8):e529-e539
pubmed: 35543633
J Nucl Med. 2016 Jun;57(6):872-8
pubmed: 26769864
BMC Cancer. 2017 Feb 23;17(1):154
pubmed: 28231773
Diagnostics (Basel). 2022 Mar 29;12(4):
pubmed: 35453892
J Nucl Med. 2022 Nov;63(11):1644-1650
pubmed: 35301240
Eur J Nucl Med Mol Imaging. 2022 Oct;49(12):4271-4281
pubmed: 35767071